SYNBIOMATICA

Daily briefings

Editor’s Briefing: November 19, 2026

In Short. The FDA approved Sanofi's Infilbray for a rare inherited disease and Regeneron's Livsayis for a muscle-weakness disease. Bristol Myers Squibb reported open-label Phase 3 results for KarXT in Alzheimer's psychosis.

The FDA approves Sanofi's Infilbray for neurological symptoms of Type 3 Gaucher disease

GAUCHER disease is a rare inherited illness in which a missing enzyme lets certain fats build up in organs and, in Type 3 disease, in the brain. On Wednesday the FDA approved Sanofi's Infilbray (venglustat) (announcement). The once-daily pill is approved for the neurological manifestations of Type 3 Gaucher disease in adults and children who weigh at least 15 kilograms. It is designed to block an enzyme that makes those fats and to reach the brain, which enzyme-replacement infusions do not treat well.

The approval rests on LEAP2MONO, a Phase 3 trial that assigned 43 people aged 12 and older at random, in equal groups. They received the pill or imiglucerase, an enzyme-replacement infusion given every two weeks. All had already been treated with enzyme replacement for at least three years and had stable disease outside the brain. A combined test of coordination and thinking scores at week 52 found the pill superior (p=0.0137). The company did not report the size of the changes on the individual scales. Among 21 people on the pill and 22 on the infusion, diarrhea occurred in 14% versus none, and nausea in 14% versus 5%. The label warns about suicidal thoughts, clouding of the lens in children, and harm to a fetus.

The FDA approves Regeneron's Livsayis for generalized myasthenia gravis

GENERALIZED myasthenia gravis is an autoimmune disease in which antibodies against a muscle receptor interrupt signals from nerve to muscle, causing weakness that can affect speech, swallowing, breathing, and movement. On Wednesday evening the FDA approved Regeneron's Livsayis (cemdisiran) for adults whose disease is driven by those antibodies (announcement). The medicine is a short RNA, given as an injection under the skin every three months, that reduces production of a complement protein called C5.

The approval rests on NIMBLE, a Phase 3 trial. Of 284 people assigned at random to one of four injection regimens, the main comparison was between 64 people on Livsayis every three months and 59 on placebo. That comparison covered 24 weeks. A daily-function score improved by 4.5 points on Livsayis and by 2.2 points on placebo, a difference of 2.3 points (p=0.0005). A clinician measure of muscle strength improved by 4.2 points versus 1.5 points, and the trial estimated the difference at 2.8 points (p=0.0015). The label carries a boxed warning for serious meningococcal infections, including a risk of death, and the medicine is available only through a restricted safety program. In the placebo-controlled period, among 79 people on Livsayis and 72 on placebo, reactions at the injection site occurred in 8% versus 3%. Viral infections occurred in 6% versus 4%, and urinary infections in 5% versus 4%.

Bristol Myers Squibb reports open-label Phase 3 results for KarXT in Alzheimer's psychosis

ALZHEIMER'S disease can cause psychosis, meaning hallucinations and delusions, in addition to memory loss. On Wednesday morning Bristol Myers Squibb reported the first results from two Phase 3 studies of KarXT (xanomeline and trospium chloride) in that setting (announcement). The same medicine is already approved as Cobenfy for schizophrenia in adults. The new analyses come from open-label periods, in which clinicians and participants knew they were receiving the medicine, and there was no comparison group. The later double-blind parts of the program remain blinded.

In ADEPT-1, 273 of 320 enrolled people (85.3%) completed a 12-week open-label period. A clinician scale of hallucinations and delusions fell by a mean of 12.0 points from a starting score of 14.4 among 266 people. A severity scale fell by 1.9 points from 4.5 among 267 people. In ADEPT-3, a 52-week extension, 273 of 401 enrolled people (68.1%) completed treatment. The hallucination-and-delusion score fell by 5.1 points from 8.9 among 270 people, and the severity score fell by 0.8 points from 3.4 among 277 people. The company said there were no new safety signals and did not describe the types of serious unwanted effects.

What to watch

By November 22 the FDA is due to decide on Capricor's deramiocel for Duchenne muscular dystrophy, and on Savara's inhaled molgramostim. Molgramostim is intended for autoimmune pulmonary alveolar proteinosis, a rare disease in which a protein-rich fluid builds up in the lungs. A decision on BridgeBio's BBP-418 for limb-girdle muscular dystrophy type 2I/R9, an inherited muscle-wasting disease, is due on November 27.

Sources

  1. Sanofi: FDA approves Infilbray
  2. Regeneron: Livsayis (cemdisiran) approved by FDA, first siRNA therapy in its cla
  3. Livsayis full prescribing information
  4. Bristol Myers Squibb: first clinical data from two Phase 3 ADEPT studies of KarX
  5. FDA: novel drug approvals 2026